U.S. Vaccine Market

Vaccine is a biological component that promotes the formation of antibodies against various infections already present in the body. It is typically created utilizing pathogens and chemical medications that serve as antigens to ward off sickness. Conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines are the most common types in the market. They aid in the prevention of several serious illnesses, such as hepatitis, measles, polio, diphtheria, meningitis, influenza, tetanus, and rotavirus. As the number of reported COVID cases increased overall, people worldwide anticipated a vaccine capable of combating the virus. The vaccine market is expected to develop due to the rising demand for coronavirus vaccines. Governments and medical regulators accelerated vaccine development due to the epidemic's severity, even though normal vaccine development needed years to complete the necessary testing. Factors such as the growing prevalence of infectious diseases, innovative technology in vaccine development, increased funding from government and international organizations, and the increasing government focus on immunization programs are boosting the market's growth.

Market Dynamics

The key market players are focusing on the adoption of growth and organic strategies such as Launch of new vaccines, which is attributed to the growth of the U.S. Vaccines market. For Instance, in March 2021, Ocugen Inc., a biotech company in the U.S., announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening the study of its COVID-19 vaccine candidate, COVAXIN (BBV152; Clinicaltrials.gov, NCT05258669), a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades. COVAXIN, an inactivated virus vaccine adjuvanted with TLR7/8 agonist, has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein; whereas currently approved vaccines in the U.S. target only S-protein antigen. Additionally, in contrast to other inactivated vaccines, clinical trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.

Key features of the study:

• This report provides an in-depth analysis of the S. vaccines market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. vaccines market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi Pasteur, GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, Boehringer Ingelheim, Bharat Biotech., BIO-MED, Serum Institute of India Pvt. Ltd., Kedrion Biopharma Inc. GlaxoSmithKline plc., Bilthoven Biologicals, Cadila Healthcare Limited, Sanofi Pasteur India Pvt Ltd, Chiron Behring Vaccines Private Ltd, Zoetis Inc., Elanco., Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd, Wyeth pharmaceuticals, Berna Biotech Ltd., Novartis Vaccines Ltd, and Medimmune LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• U.S. vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. vaccines market

Detailed Segmentation:

• U.S. Vaccines Market, By Product Type:
  • Human Vaccine
    • Pediatric Vaccines
    • Adult & Adolescent Vaccines
    • Other Human Vaccines
  • Animal Vaccine
    • Livestock Vaccines
    • Companion Animal Vaccines
    • Other Animal Vaccines
• U.S. Vaccines Market, By End User:
  • Hospitals
  • Clinics
  • Vaccination Centers
• Company Profiles
  • Sanofi Pasteur 
  • GlaxoSmithKline Plc
  • Merck & Company Incorporated
  • Pfizer Incorporated
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Bharat Biotech.
  • BIO-MED
  • Serum Institute of India Pvt. Ltd.
  •  Kedrion Biopharma Inc.
  • GlaxoSmithKline plc.
  • Bilthoven Biologicals
  • Cadila Healthcare Limited
  • Sanofi Pasteur India Pvt Ltd
  • Chiron Behring Vaccines Private Ltd
  • Zoetis Inc.
  • Elanco.
  • Boehringer Ingelheim International GmbH
  • Indian Immunologicals Ltd
  • Wyeth pharmaceuticals
  • Berna Biotech Ltd.
  • Novartis Vaccines Ltd
  • Medimmune LLC